The observations that CPZ had potential anti-TB activity spurred the study demonstrating that the in vitro concentrations of CPZ needed to inhibit the replication of Mtb could be exceeded and safely achieved in the CPZ treated patient, and clinically relevant concentrations ex vivo could effectively promote the killing of phagocytosed Mtb [14]. The gene discussed is CPZ; the disease is tuberculosis.